Zymeworks Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $4.6 million (-90.6% year over year) and diluted EPS of -$0.62. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
5
-90.6%
|
-45
-2043.0%
|
-0.62
-2166.7%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
-91.1%
|
-44
-95.1%
|
-0.59
-96.7%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
3
-91.9%
|
-41
-75.3%
|
-0.55
-73.9%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
28
+72.6%
|
-20
+34.3%
|
-0.26
+33.3%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
49
+153.2%
|
2
+106.1%
|
0.03
+106.1%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
27
+170.3%
|
-23
+28.5%
|
-0.30
+28.6%
|
|
Jan 8, 2025
8 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
31
+83.3%
|
-24
-62.3%
|
-0.31
-53.7%
|
|
Oct 31, 2024
31 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
16
-3.1%
|
-30
-4.1%
|
-0.39
+4.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZYME (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Middletown, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1937653
- Former names
- Zymeworks Delaware Inc. (until Oct 13, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.